NVO SEC Filing News — Novo Nordisk A/S

Latest SEC filings for Novo Nordisk A/S (NVO) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). All data sourced directly from SEC EDGAR — last updated 2025-05-30.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c…
Sector: Healthcare Industry: Drug Manufacturers - General Market Cap: $199.5B CIK: 353278
1
Total Filings
0
Bullish Signals
0
Bearish Signals
0
Insider Transactions
0
Material Events (8-K)
0
Periodic Reports
What you're looking at: Each item below is parsed from an actual SEC filing submitted by Novo Nordisk A/S. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.
Proposed Insider Sales 1 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Novo Nordisk A/S has 1 such notice in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2025-05-30

NVO Form 144 filed for proposed insider sale by Novo Nordisk A/S (921,897 shares) ~$3.95M

Novo Nordisk A/S filed a Form 144 with the SEC indicating intent to sell NVO (NOVO NORDISK A S) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Novo Nordisk A/S Shares: 921,897 Est. Value: $3.95M
View on SEC EDGAR → Open Filing Document →

How we classify Novo Nordisk A/S's filings

Straight from EDGAR

Every filing on this page is pulled from the SEC's EDGAR system for Novo Nordisk A/S and parsed directly. Nothing here is estimated or inferred from a third-party feed, and each entry links back to the original document so the underlying filing can be read in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on NVO. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — NVO SEC Filings

What SEC filings does Novo Nordisk A/S submit to the SEC?

Novo Nordisk A/S (NVO) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about NVO?

A Form 4 for NVO discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the date, number of shares bought or sold, the price, and the insider's updated total ownership. Consistent insider buying across multiple executives is often interpreted as a bullish signal.

How do I interpret an 8-K filing from Novo Nordisk A/S?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for NVO?

The 10-K is Novo Nordisk A/S's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all NVO SEC filings directly on EDGAR?

You can view all historical Novo Nordisk A/S filings on the SEC EDGAR company page for NVO. Each filing card on this page links directly to the original SEC document.

How often does Novo Nordisk A/S file with the SEC?

Novo Nordisk A/S files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling NVO shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

More Tools for NVO

NVO Full Stock Analysis NVO Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Demand Zone Analyzer Sector Scanner Browse All Stocks

Want deeper NVO analysis?

View valuation, growth metrics, AI Strong Buy score, demand zones, peer comparison, and more — all on the NVO stock analysis page.

NVO Full Analysis
SEC filing data is sourced from SEC EDGAR. This page is updated automatically as new filings are detected. Content is for informational purposes only and does not constitute investment advice. Full Disclaimer.